TechNavio today published its report Global Atrial Fibrillation Market 2010“2014. The report aims to help decision makers™ understanding of the key trends in this market.
TechNavio™s report highlights that the Global Atrial Fibrillation market is witnessing a shift towards the newer and more economical drugs and treatments. The current treatment options are moderately successful in meeting the market demand. Newer anti-arrhythmic drugs, which block multiple channels or have specificity for the atrial myocardium, are believed to present a more favorable risk-benefit ratio than traditional anti-arrhythmic drugs.
Commenting on the report, an analyst from TechNavio™s Healthcare team said, It becomes difficult for smaller companies to succeed in the Global Atrial Fibrillation market mainly because of the high development costs required for licensing, acquisitions, marketing, and manufacturing. Major reputed atrial fibrillation devices and drug vendors engage in licensing agreements with small and medium players in the pipeline. While emerging regional vendors provide marketing, sales, and regulatory support to major global atrial fibrillation vendors.
Key findings from the report:
¢ Emergence of New Anti-arrhythmic and Anti-coagulant Agents for Atrial Fibrillation
¢ Negative Effect of Global Economic Recession
¢ Increase in Number of Clinical Trials of Atrial Fibrillation Devices and Drugs
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
TechNavio, the market research platform of Infiniti Research Ltd, publishes periodic reports on niche and emerging technologies. For further information, please visit https://www.technavio.com/content/global-atrial-fibrillation-market-2010%E2%8…
Follow us on Twitter @ Technavio
Atrial Fibrillation Market Witnessing a Surge in Economical Drugs
